Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases

Bergthaler, A.; Menche, J. The immune system as a social network. Nat. Immunol., 2017, 18(5), 481-482.
[http://dx.doi.org/10.1038/ni.3727] [PMID: 28418389]

Fugger, L.; Jensen, L.T.; Rossjohn, J. Challenges, progress, and prospects of developing therapies to treat autoimmune diseases. Cell, 2020, 181(1), 63-80.
[http://dx.doi.org/10.1016/j.cell.2020.03.007] [PMID: 32243797]

Wang, F.; Tang, J.; Li, Z.; Qi, Y.; Li, G.; Wang, F. Oral methotrexate at doses 15–25 mg/week is non-inferior to parenteral regarding efficacy and safety in the treatment of rheumatoid arthritis: A systematic review and meta-analysis. Clin. Rheumatol., 2022, 41(9), 2701-2712.
[http://dx.doi.org/10.1007/s10067-022-06221-z] [PMID: 35672619]

Soelberg Sorensen, P. Safety concerns and risk management of multiple sclerosis therapies. Acta Neurol. Scand., 2017, 136(3), 168-186.
[http://dx.doi.org/10.1111/ane.12712] [PMID: 27891572]

Hofmann, K.; Clauder, A.K.; Manz, R.A. Targeting B cells and plasma cells in autoimmune diseases. Front. Immunol., 2018, 9, 835.
[http://dx.doi.org/10.3389/fimmu.2018.00835] [PMID: 29740441]

Corneth, O.B.J.; Klein Wolterink, R.G.J.; Hendriks, R.W. BTK signaling in B cell differentiation and autoimmunity. Curr. Top. Microbiol. Immunol., 2015, 393, 67-105.
[http://dx.doi.org/10.1007/82_2015_478] [PMID: 26341110]

Rozkiewicz, D.; Hermanowicz, J.M.; Kwiatkowska, I.; Krupa, A.; Pawlak, D. Bruton’s tyrosine kinase inhibitors (BTKIs): Review of preclinical studies and evaluation of clinical trials. Molecules, 2023, 28(5), 2400.
[http://dx.doi.org/10.3390/molecules28052400] [PMID: 36903645]

Allen, R.C.; Nachtman, R.G.; Rosenblatt, H.M.; Belmont, J.W. Application of carrier testing to genetic counseling for X-linked agammaglobulinemia. Am. J. Hum. Genet., 1994, 54(1), 25-35.
[PMID: 7506482]

Rawlings, D.J.; Saffran, D.C.; Tsukada, S.; Largaespada, D.A.; Grimaldi, J.C.; Cohen, L.; Mohr, R.N.; Bazan, J.F.; Howard, M.; Copeland, N.G.; Jenkins, N.A.; Witte, O.N. Mutation of unique region of Bruton’s tyrosine kinase in immunodeficient XID mice. Science, 1993, 261(5119), 358-361.
[http://dx.doi.org/10.1126/science.8332901] [PMID: 8332901]

Thomas, J.D.; Sideras, P.; Smith, C.I.E.; Vořechovský, I.; Chapman, V.; Paul, W.E. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science, 1993, 261(5119), 355-358.
[http://dx.doi.org/10.1126/science.8332900] [PMID: 8332900]

Tsukada, S.; Saffran, D.C.; Rawlings, D.J.; Parolini, O.; Allen, R.C.; Klisak, I.; Sparkes, R.S.; Kubagawa, H.; Mohandas, T.; Quan, S.; Belmont, J.W.; Cooper, M.D.; Conley, M.E.; Witte, O.N. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell, 1993, 72(2), 279-290.
[http://dx.doi.org/10.1016/0092-8674(93)90667-F] [PMID: 8425221]

Ponader, S.; Burger, J.A. Bruton’s tyrosine kinase: From X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J. Clin. Oncol., 2014, 32(17), 1830-1839.
[http://dx.doi.org/10.1200/JCO.2013.53.1046] [PMID: 24778403]

Smith, C.I.E.; Islam, T.C.; Mattsson, P.T.; Mohamed, A.J.; Nore, B.F.; Vihinen, M. The Tec family of cytoplasmic tyrosine kinases: Mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. BioEssays, 2001, 23(5), 436-446.
[http://dx.doi.org/10.1002/bies.1062] [PMID: 11340625]

Wahl, M.I.; Fluckiger, A.C.; Kato, R.M.; Park, H.; Witte, O.N.; Rawlings, D.J. Phosphorylation of two regulatory tyrosine residues in the activation of Bruton’s tyrosine kinase via alternative receptors. Proc. Natl. Acad. Sci., 1997, 94(21), 11526-11533.
[http://dx.doi.org/10.1073/pnas.94.21.11526] [PMID: 9326643]

Wang, H.; Guo, H.; Yang, J.; Liu, Y.; Liu, X.; Zhang, Q.; Zhou, K. Bruton tyrosine kinase inhibitors in B-cell lymphoma: Beyond the antitumour effect. Exp. Hematol. Oncol., 2022, 11(1), 60.
[http://dx.doi.org/10.1186/s40164-022-00315-9] [PMID: 36138486]

Gozzetti, A.; Candi, V.; Brambilla, C.Z.; Papini, G.; Fabbri, A.; Bocchia, M. Bruton kinase inhibitors in chronic lymphocytic leukemia. Anticancer. Agents Med. Chem., 2017, 17(8), 1040-1045.
[PMID: 27697038]

Dong, Y.; Pi, X.; Bartels-Burgahn, F.; Saltukoglu, D.; Liang, Z.; Yang, J.; Alt, F.W.; Reth, M.; Wu, H. Structural principles of B cell antigen receptor assembly. Nature, 2022, 612(7938), 156-161.
[http://dx.doi.org/10.1038/s41586-022-05412-7] [PMID: 36228656]

Burger, J.A. Bruton tyrosine kinase inhibitors: Present and future. Cancer J., 2019, 25(6), 386-393.
[http://dx.doi.org/10.1097/PPO.0000000000000412] [PMID: 31764119]

Cameron, F.; Sanford, M. Ibrutinib: First global approval. Drugs, 2014, 74(2), 263-271.
[http://dx.doi.org/10.1007/s40265-014-0178-8] [PMID: 24464309]

Keam, S.J. Ibrutinib: Pediatric first approval. Paediatr. Drugs, 2023, 25(1), 127-133.
[http://dx.doi.org/10.1007/s40272-022-00543-w] [PMID: 36352302]

Karr, M.; Roeker, L. A history of targeted therapy development and progress in novel-novel combinations for chronic lymphocytic leukemia (CLL). Cancers, 2023, 15(4), 1018.
[http://dx.doi.org/10.3390/cancers15041018] [PMID: 36831364]

Szklener, K.; Michalski, A.; Żak, K.; Piwoński, M.; Mańdziuk, S. Ibrutinib in the treatment of solid tumors: Current state of knowledge and future directions. Cells, 2022, 11(8), 1338.
[http://dx.doi.org/10.3390/cells11081338] [PMID: 35456016]

Salem, J.E.; Manouchehri, A.; Bretagne, M.; Lebrun-Vignes, B.; Groarke, J.D.; Johnson, D.B.; Yang, T.; Reddy, N.M.; Funck-Brentano, C.; Brown, J.R.; Roden, D.M.; Moslehi, J.J. Cardiovascular toxicities associated with ibrutinib. J. Am. Coll. Cardiol., 2019, 74(13), 1667-1678.
[http://dx.doi.org/10.1016/j.jacc.2019.07.056] [PMID: 31558250]

Mato, A.R.; Nabhan, C.; Thompson, M.C.; Lamanna, N.; Brander, D.M.; Hill, B.; Howlett, C.; Skarbnik, A.; Cheson, B.D.; Zent, C.; Pu, J.; Kiselev, P.; Goy, A.; Claxton, D.; Isaac, K.; Kennard, K.H.; Timlin, C.; Landsburg, D.; Winter, A.; Nasta, S.D.; Bachow, S.H.; Schuster, S.J.; Dorsey, C.; Svoboda, J.; Barr, P.; Ujjani, C.S. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: A real-world analysis. Haematologica, 2018, 103(5), 874-879.
[http://dx.doi.org/10.3324/haematol.2017.182907] [PMID: 29419429]

Honigberg, L.A.; Smith, A.M.; Sirisawad, M.; Verner, E.; Loury, D.; Chang, B.; Li, S.; Pan, Z.; Thamm, D.H.; Miller, R.A.; Buggy, J.J. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci., 2010, 107(29), 13075-13080.
[http://dx.doi.org/10.1073/pnas.1004594107] [PMID: 20615965]

Markham, A.; Dhillon, S. Acalabrutinib:First global approval. Drugs, 2018, 78(1), 139-145.
[http://dx.doi.org/10.1007/s40265-017-0852-8] [PMID: 29209955]

Awan, F.T.; Schuh, A.; Brown, J.R.; Furman, R.R.; Pagel, J.M.; Hillmen, P.; Stephens, D.M.; Woyach, J.; Bibikova, E.; Charuworn, P.; Frigault, M.M.; Hamdy, A.; Izumi, R.; Linghu, B.; Patel, P.; Wang, M.H.; Byrd, J.C. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv., 2019, 3(9), 1553-1562.
[http://dx.doi.org/10.1182/bloodadvances.2018030007] [PMID: 31088809]

Byrd, J.C.; Hillmen, P.; Ghia, P.; Kater, A.P.; Chanan-Khan, A.; Furman, R.R.; O’Brien, S.; Yenerel, M.N.; Illés, A.; Kay, N.; Garcia-Marco, J.A.; Mato, A.; Pinilla-Ibarz, J.; Seymour, J.F.; Lepretre, S.; Stilgenbauer, S.; Robak, T.; Rothbaum, W.; Izumi, R.; Hamdy, A.; Patel, P.; Higgins, K.; Sohoni, S.; Jurczak, W. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial. J. Clin. Oncol., 2021, 39(31), 3441-3452.
[http://dx.doi.org/10.1200/JCO.21.01210] [PMID: 34310172]

Furman, R.R.; Byrd, J.C.; Owen, R.G.; O’Brien, S.M.; Brown, J.R.; Hillmen, P.; Stephens, D.M.; Chernyukhin, N.; Lezhava, T.; Hamdy, A.M.; Izumi, R.; Patel, P.; Baek, M.; Christian, B.; Dyer, M.J.S.; Streetly, M.J.; Sun, C.; Rule, S.; Wang, M.; Ghia, P.; Jurczak, W.; Pagel, J.M.; Sharman, J.P. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia, 2021, 35(11), 3201-3211.
[http://dx.doi.org/10.1038/s41375-021-01252-y] [PMID: 33907299]

Zhu, S.; Jung, J.; Victor, E.; Arceo, J.; Gokhale, S.; Xie, P. Clinical trials of the BTK inhibitors Ibrutinib and Acalabrutinib in human diseases beyond B cell malignancies. Front. Oncol., 2021, 11, 737943.
[http://dx.doi.org/10.3389/fonc.2021.737943] [PMID: 34778053]

Syed, Y.Y. Zanubrutinib: First approval. Drugs, 2020, 80(1), 91-97.
[http://dx.doi.org/10.1007/s40265-019-01252-4] [PMID: 31933167]

Tam, C.S.; Trotman, J.; Opat, S.; Burger, J.A.; Cull, G.; Gottlieb, D.; Harrup, R.; Johnston, P.B.; Marlton, P.; Munoz, J.; Seymour, J.F.; Simpson, D.; Tedeschi, A.; Elstrom, R.; Yu, Y.; Tang, Z.; Han, L.; Huang, J.; Novotny, W.; Wang, L.; Roberts, A.W. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood, 2019, 134(11), 851-859.
[http://dx.doi.org/10.1182/blood.2019001160] [PMID: 31340982]

Tam, C.S.; Dimopoulos, M.; Garcia-Sanz, R.; Trotman, J.; Opat, S.; Roberts, A.W.; Owen, R.; Song, Y.; Xu, W.; Zhu, J.; Li, J.; Qiu, L.; D’Sa, S.; Jurczak, W.; Cull, G.; Marlton, P.; Gottlieb, D.; Munoz, J.; Phillips, T.; Du, C.; Ji, M.; Zhou, L.; Guo, H.; Zhu, H.; Chan, W.Y.; Cohen, A.; Novotny, W.; Huang, J.; Tedeschi, A. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv., 2022, 6(4), 1296-1308.
[http://dx.doi.org/10.1182/bloodadvances.2021005621] [PMID: 34724705]

Killock, D. Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL. Nat. Rev. Clin. Oncol., 2023, 20(2), 64.
[http://dx.doi.org/10.1038/s41571-022-00724-z] [PMID: 36543933]

Brown, J.R.; Eichhorst, B.; Hillmen, P.; Jurczak, W.; Kaźmierczak, M.; Lamanna, N.; O’Brien, S.M.; Tam, C.S.; Qiu, L.; Zhou, K.; Simkovic, M.; Mayer, J.; Gillespie-Twardy, A.; Ferrajoli, A.; Ganly, P.S.; Weinkove, R.; Grosicki, S.; Mital, A.; Robak, T.; Osterborg, A.; Yimer, H.A.; Salmi, T.; Wang, M.D.Y.; Fu, L.; Li, J.; Wu, K.; Cohen, A.; Shadman, M. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N. Engl. J. Med., 2023, 388(4), 319-332.
[http://dx.doi.org/10.1056/NEJMoa2211582] [PMID: 36511784]

Dhillon, S. Orelabrutinib: First approval. Drugs, 2021, 81(4), 503-507.
[http://dx.doi.org/10.1007/s40265-021-01482-5] [PMID: 33704654]

Xu, W.; Zhou, K.; Wang, T.; Yang, S.; Liu, L.; Hu, Y.; Zhang, W.; Ding, K.; Zhou, J.; Gao, S.; Xu, B.; Zhu, Z.; Liu, T.; Zhang, H.; Hu, J.; Ji, C.; Wang, S.; Xia, Z.; Wang, X.; Li, Y.; Song, Y.; Ma, S.; Tang, X.; Zhang, B.; Li, J. Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study. Am. J. Hematol., 2023, 98(4), 571-579.
[http://dx.doi.org/10.1002/ajh.26826] [PMID: 36683422]

Gu, D.; Li, J.; Miao, Y. Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China. Expert Opin. Pharmacother., 2022, 23(18), 1979-1986.
[http://dx.doi.org/10.1080/14656566.2022.2144218] [PMID: 36329558]

Dhillon, S. Tirabrutinib: First approval. Drugs, 2020, 80(8), 835-840.
[http://dx.doi.org/10.1007/s40265-020-01318-8] [PMID: 32382949]

Munakata, W.; Ando, K.; Yokoyama, M.; Fukuhara, N.; Yamamoto, K.; Fukuhara, S.; Ohmachi, K.; Mishima, Y.; Ichikawa, S.; Ogiya, D.; Aoi, A.; Hatsumichi, M.; Tobinai, K. Long-term safety profile of tirabrutinib: Final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies. Int. J. Hematol., 2023, 117(4), 553-562.
[http://dx.doi.org/10.1007/s12185-022-03514-6] [PMID: 36576659]

Sekiguchi, N.; Rai, S.; Munakata, W.; Suzuki, K.; Handa, H.; Shibayama, H.; Endo, T.; Terui, Y.; Iwaki, N.; Fukuhara, N.; Tatetsu, H.; Iida, S.; Ishikawa, T.; Iguchi, D.; Izutsu, K. Two-year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia. Cancer Sci., 2022, 113(6), 2085-2096.
[http://dx.doi.org/10.1111/cas.15344] [PMID: 35332633]

Keam, S.J. Pirtobrutinib: First approval. Drugs, 2023, 83(6), 547-553.
[http://dx.doi.org/10.1007/s40265-023-01860-1] [PMID: 37004673]

Gomez, E.B.; Ebata, K.; Randeria, H.S.; Rosendahl, M.S.; Cedervall, E.P.; Morales, T.H.; Hanson, L.M.; Brown, N.E.; Gong, X.; Stephens, J.R.; Wu, W.; Lippincott, I.; Ku, K.S.; Walgren, R.A.; Abada, P.B.; Ballard, J.A.; Allerston, C.K.; Brandhuber, B.J. Pirtobrutinib preclinical characterization: A highly selective, non-covalent (reversible) BTK inhibitor. Blood, 2023, 142(1), 2022018674.
[http://dx.doi.org/10.1182/blood.2022018674] [PMID: 36796019]

Mato, A.R.; Shah, N.N.; Jurczak, W.; Cheah, C.Y.; Pagel, J.M.; Woyach, J.A.; Fakhri, B.; Eyre, T.A.; Lamanna, N.; Patel, M.R.; Alencar, A.; Lech-Maranda, E.; Wierda, W.G.; Coombs, C.C.; Gerson, J.N.; Ghia, P.; Le Gouill, S.; Lewis, D.J.; Sundaram, S.; Cohen, J.B.; Flinn, I.W.; Tam, C.S.; Barve, M.A.; Kuss, B.; Taylor, J.; Abdel-Wahab, O.; Schuster, S.J.; Palomba, M.L.; Lewis, K.L.; Roeker, L.E.; Davids, M.S.; Tan, X.N.; Fenske, T.S.; Wallin, J.; Tsai, D.E.; Ku, N.C.; Zhu, E.; Chen, J.; Yin, M.; Nair, B.; Ebata, K.; Marella, N.; Brown, J.R.; Wang, M. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1/2 study. Lancet, 2021, 397(10277), 892-901.
[http://dx.doi.org/10.1016/S0140-6736(21)00224-5] [PMID: 33676628]

Wang, E.; Mi, X.; Thompson, M.C.; Montoya, S.; Notti, R.Q.; Afaghani, J.; Durham, B.H.; Penson, A.; Witkowski, M.T.; Lu, S.X.; Bourcier, J.; Hogg, S.J.; Erickson, C.; Cui, D.; Cho, H.; Singer, M.; Totiger, T.M.; Chaudhry, S.; Geyer, M.; Alencar, A.; Linley, A.J.; Palomba, M.L.; Coombs, C.C.; Park, J.H.; Zelenetz, A.; Roeker, L.; Rosendahl, M.; Tsai, D.E.; Ebata, K.; Brandhuber, B.; Hyman, D.M.; Aifantis, I.; Mato, A.; Taylor, J.; Abdel-Wahab, O. Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors. N. Engl. J. Med., 2022, 386(8), 735-743.
[http://dx.doi.org/10.1056/NEJMoa2114110] [PMID: 35196427]

von Hundelshausen, P.; Siess, W. Bleeding by Bruton tyrosine kinase-inhibitors: Dependency on drug type and disease. Cancers, 2021, 13(5), 1103.
[http://dx.doi.org/10.3390/cancers13051103] [PMID: 33806595]

Dhami, K.; Chakraborty, A.; Gururaja, T.L.; Cheung, L.W.K.; Sun, C.; DeAnda, F.; Huang, X. Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK. Sci. Signal., 2022, 15(736), eabg5216.
[http://dx.doi.org/10.1126/scisignal.abg5216] [PMID: 35639855]

Li, K.; Crews, C.M. PROTACs: Past, present and future. Chem. Soc. Rev., 2022, 51(12), 5214-5236.
[http://dx.doi.org/10.1039/D2CS00193D] [PMID: 35671157]

Robbins, D.W.; Kelly, A.; Tan, M.; McIntosh, J.; Wu, J.; Konst, Z.; Kato, D.; Peng, G.; Mihalic, J.; Weiss, D.; Perez, L.; Tung, J.; Kolobova, A.; Borodovsky, S.; Rountree, R.; Tenn-McClellan, A.; Noviski, M.; Ye, J.; Basham, S.; Ingallinera, T.; McKinnell, J.; Karr, D.E.; Powers, J.; Guiducci, C.; Sands, A. Nx-2127, a degrader of BTK and IMiD neosubstrates, for the treatment of B-cell malignancies. Blood, 2020, 136(Suppl. 1), 34.
[http://dx.doi.org/10.1182/blood-2020-141461]

Scarfò, L. Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax. Hematology (Am. Soc. Hematol. Educ. Program), 2022, 2022(1), 316-322.
[http://dx.doi.org/10.1182/hematology.2022000344] [PMID: 36485153]

Montoya, S.; Bourcier, J.; Thompson, M.C.; Noviski, M.; Tan, M.; Wang, E.; Mi, X.; Brathaban, N.; Barrientos Risso, C.; Tsai, D.; Ye, J.; Jahn, J.; Pardo, G.; Cabuhat, L.; Notti, R.; Pardo, A.; Affer, M.; Yung, S.; Luliano, J.; Powers, J.; Robbins, D.W.; Nawaratne, V.; Totiger, T.M.; Pena-Velasquez, C.; Rhodes, J.M.; Zelenetz, A.D.; Roeker, L.E.; Lu, H.; Linley, A.; Mato, A.R.; Abdel-Wahab, O.; Taylor, J. Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders. Blood, 2022, 140(Suppl. 1), 1811-1813.
[http://dx.doi.org/10.1182/blood-2022-163268]

McDonald, C.; Xanthopoulos, C.; Kostareli, E. The role of Bruton’s tyrosine kinase in the immune system and disease. Immunology, 2021, 164(4), 722-736.
[http://dx.doi.org/10.1111/imm.13416] [PMID: 34534359]

Carnero Contentti, E.; Correale, J. Current perspectives: Evidence to date on BTK inhibitors in the management of multiple sclerosis. Drug Des. Devel. Ther., 2022, 16, 3473-3490.
[http://dx.doi.org/10.2147/DDDT.S348129] [PMID: 36238195]

Cheung, T.T.; McInnes, I.B. Future therapeutic targets in rheumatoid arthritis? Semin. Immunopathol., 2017, 39(4), 487-500.
[http://dx.doi.org/10.1007/s00281-017-0623-3] [PMID: 28451787]

Seyferth, A.V.; Cichocki, M.N.; Wang, C.W.; Huang, Y.J.; Huang, Y.W.; Chen, J.S.; Kuo, C.F.; Chung, K.C. Factors associated with quality care among adults with rheumatoid arthritis. JAMA Netw. Open, 2022, 5(12), e2246299.
[http://dx.doi.org/10.1001/jamanetworkopen.2022.46299] [PMID: 36508216]

Goess, C.; Harris, C.M.; Murdock, S.; McCarthy, R.W.; Sampson, E.; Twomey, R.; Mathieu, S.; Mario, R.; Perham, M.; Goedken, E.R.; Long, A.J. ABBV-105, a selective and irreversible inhibitor of Bruton’s tyrosine kinase, is efficacious in multiple preclinical models of inflammation. Mod. Rheumatol., 2019, 29(3), 510-522.
[http://dx.doi.org/10.1080/14397595.2018.1484269] [PMID: 29862859]

Cohen, S.; Tuckwell, K.; Katsumoto, T.R.; Zhao, R.; Galanter, J.; Lee, C.; Rae, J.; Toth, B.; Ramamoorthi, N.; Hackney, J.A.; Berman, A.; Damjanov, N.; Fedkov, D.; Jeka, S.; Chinn, L.W.; Townsend, M.J.; Morimoto, A.M.; Genovese, M.C.; Berman, A.; Porto, A.; Granel, A.; Asnal, C.; Mysler, E.F.; Testa, G.A.; Zamora, J.L.V.; Moreno, J.L.C.; Gulin, J.P.; Hofman, J.; Ulla, M.R.; Sabelli, M.; Mannucci, P.A.; Maid, P.J.; Melazzi, A.C.C.; Scotton, A.S.; Ximenes, A.C.; Funes, E.; Gimenez, E.A.; Marcolino, F.M.D.A.; Neto, J.F.M.; Keiserman, M.W.; Radominski, S.C.; Lima, S.M.A.A.L.; Pavan, T.R.; Azevedo, V.F.; Koleva, A.; Toncheva, A.; Bichovska, D.; Ivanova, D.; Penev, D.; Dimitrov, E.; Mihaylova, M.; Kapandjieva, N.; Marinova, N.; Aleksieva, T.; Tsvetanova, T.; Petranova, T.; Popova, V.; Spasov, Y.; Toro, C.E.; Arteaga Unigarro, C.E.; Jauregui, E.; Hernandez, J.D.M.; Raad, J.J.J.; Sanchez, P.J.V.; Lee, C.K.; Suh, C-H.; Lee, E.Y.; Lee, S-H.; Kang, S.W.; Lee, S-S.; Lee, Y.J.; Montiel, B.E.Z.; Pinzon de la O, B.I.; Friedmann, D.X.; Lopez, F.R.; Torres, I.R.; Quezada, L.J.; Ceceña, M.M.; Hernandez, M.C.; Salinas, M.S.; Rapa, A.; Pawtel, A.; Zielinska, A.; Dudek, A.; Rychlewska-Hanczewska, A.; Strzelecka, A.; Racewicz, A.; Stasiuk, B.; Gruszecka, K.; Dworak, K.; Jeka, S.; Lowenhoff, T.; Maslyanskiy, A.; Rebrov, A.; Krechikova, D.; Zhugrova, E.; Shmidt, E.; Matsievskaya, G.; Vinogradova, I.; Ler, I.; Eliseeva, L.; Savina, L.; Stanislav, M.; Sandin, M.; Zyablova, N.; Korshunov, N.; Mosesova, N.; Polovnikova, O.; Nesmeyanova, O.; Samigullina, R.; Moiseev, S.; Noskov, S.; Raskina, T.; Popova, T.; Marchenko, V.; Jovanovski, A.; Stamenkovic, B.; Ristic, G.; Lazarevic, M.; Veselinovic, M.; Vujasinovic-Stupar, N.; Damjanov, N.; Ostojic, P.; Yagensky, A.; Gnylorybov, A.; Rekalov, D.; Reshotko, D.; Fedkov, D.; Dzyak, G.; Gasanov, I.; Khimion, L.; Stanislavchuk, M.; Prykhodko, N.; Nadashkevych, O.; Bortkevych, O.; Abrahamovych, O.; Yatsyshyn, R.; Turyanytsya, S.; Smiyan, S.; Vizir, V.; Kachur, V.; Tseluyko, V.; Povoroznyuk, V.; Koshlia, V.; Zhdan, V.; Lymar, Y.; Mostovoy, Y.; Hawkes, A.; Mabaquiao, A.; Chu, C-Q.; Scoville, C.; Wyatt, D.; Weinstein, D.; McIlwain, H.; Vo, J.; Poiley, J.; Forstot, J.; Dao, K.; Turner, M.; Genovese, M.; Borofsky, M.; Caldron, P.; Waller, P.; Levin, R.; Metyas, S.; Stein, S.; Shroff, S.; Pang, S.; Cohen, S.; Syed, T.; Chindalore, V. Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: A randomized, double-blind, phase II trial (ANDES study). Arthritis Rheumatol., 2020, 72(9), 1435-1446.
[http://dx.doi.org/10.1002/art.41275] [PMID: 32270926]

Crawford, J.J.; Johnson, A.R.; Misner, D.L.; Belmont, L.D.; Castanedo, G.; Choy, R.; Coraggio, M.; Dong, L.; Eigenbrot, C.; Erickson, R.; Ghilardi, N.; Hau, J.; Katewa, A.; Kohli, P.B.; Lee, W.; Lubach, J.W.; McKenzie, B.S.; Ortwine, D.F.; Schutt, L.; Tay, S.; Wei, B.; Reif, K.; Liu, L.; Wong, H.; Young, W.B. Discovery of GDC-0853: A potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development. J. Med. Chem., 2018, 61(6), 2227-2245.
[http://dx.doi.org/10.1021/acs.jmedchem.7b01712] [PMID: 29457982]

Reiff, S.D.; Muhowski, E.M.; Guinn, D.; Lehman, A.; Fabian, C.A.; Cheney, C.; Mantel, R.; Smith, L.; Johnson, A.J.; Young, W.B.; Johnson, A.R.; Liu, L.; Byrd, J.C.; Woyach, J.A. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: A new treatment strategy for ibrutinib-resistant CLL. Blood, 2018, 132(10), 1039-1049.
[http://dx.doi.org/10.1182/blood-2017-10-809020] [PMID: 30018078]

Genovese, M.C.; Spindler, A.; Sagawa, A.; Park, W.; Dudek, A.; Kivitz, A.; Chao, J.; Chan, L.S.M.; Witcher, J.; Barchuk, W.; Nirula, A. Safety and efficacy of poseltinib, Bruton’s tyrosine kinase inhibitor, in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled, 2-part phase II study. J. Rheumatol., 2021, 48(7), 969-976.
[http://dx.doi.org/10.3899/jrheum.200893] [PMID: 33323529]

Langrish, C.L.; Bradshaw, J.M.; Francesco, M.R.; Owens, T.D.; Xing, Y.; Shu, J.; LaStant, J.; Bisconte, A.; Outerbridge, C.; White, S.D.; Hill, R.J.; Brameld, K.A.; Goldstein, D.M.; Nunn, P.A. Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease. J. Immunol., 2021, 206(7), 1454-1468.
[http://dx.doi.org/10.4049/jimmunol.2001130] [PMID: 33674445]

Murrell, D.F.; Patsatsi, A.; Stavropoulos, P.; Baum, S.; Zeeli, T.; Kern, J.S.; Roussaki-Schulze, A.V.; Sinclair, R.; Bassukas, I.D.; Thomas, D.; Neale, A.; Arora, P.; Caux, F.; Werth, V.P.; Gourlay, S.G.; Joly, P. Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: The phase II BELIEVE study. Br. J. Dermatol., 2021, 185(4), 745-755.
[http://dx.doi.org/10.1111/bjd.20431] [PMID: 33942286]

Eda, H.; Santo, L.; Cirstea, D.D.; Yee, A.J.; Scullen, T.A.; Nemani, N.; Mishima, Y.; Waterman, P.R.; Arastu-Kapur, S.; Evans, E.; Singh, J.; Kirk, C.J.; Westlin, W.F.; Raje, N.S. A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity. Leukemia, 2014, 28(9), 1892-1901.
[http://dx.doi.org/10.1038/leu.2014.69] [PMID: 24518207]

Schafer, P.H.; Kivitz, A.J.; Ma, J.; Korish, S.; Sutherland, D.; Li, L.; Azaryan, A.; Kosek, J.; Adams, M.; Capone, L.; Hur, E.M.; Hough, D.R.; Ringheim, G.E. Spebrutinib (CC-292) affects markers of B cell activation, chemotaxis, and osteoclasts in patients with rheumatoid arthritis: Results from a mechanistic study. Rheumatol. Ther., 2020, 7(1), 101-119.
[http://dx.doi.org/10.1007/s40744-019-00182-7] [PMID: 31721017]

Meng, A.; Humeniuk, R.; Jürgensmeier, J.M.; Hsueh, C.H.; Matzkies, F.; Grant, E.; Truong, H.; Billin, A.N.; Yu, H.; Feng, J.; Kwan, E.; Tarnowski, T.; Nelson, C.H. Semi-mechanistic PK/PD modeling and simulation of irreversible BTK inhibition to support dose selection of tirabrutinib in subjects with RA. Clin. Pharmacol. Ther., 2022, 111(2), 416-424.
[http://dx.doi.org/10.1002/cpt.2439] [PMID: 34623640]

Makhani, N.; Tremlett, H. The multiple sclerosis prodrome. Nat. Rev. Neurol., 2021, 17(8), 515-521.
[http://dx.doi.org/10.1038/s41582-021-00519-3] [PMID: 34155379]

García-Merino, A. Bruton’s tyrosine kinase inhibitors: A new generation of promising agents for multiple sclerosis therapy. Cells, 2021, 10(10), 2560.
[http://dx.doi.org/10.3390/cells10102560] [PMID: 34685540]

Geladaris, A.; Torke, S.; Weber, M.S. Bruton’s tyrosine kinase inhibitors in multiple sclerosis: Pioneering the path towards treatment of progression? CNS Drugs, 2022, 36(10), 1019-1030.
[http://dx.doi.org/10.1007/s40263-022-00951-z] [PMID: 36178589]

Caldwell, R.D.; Qiu, H.; Askew, B.C.; Bender, A.T.; Brugger, N.; Camps, M.; Dhanabal, M.; Dutt, V.; Eichhorn, T.; Gardberg, A.S.; Goutopoulos, A.; Grenningloh, R.; Head, J.; Healey, B.; Hodous, B.L.; Huck, B.R.; Johnson, T.L.; Jones, C.; Jones, R.C.; Mochalkin, I.; Morandi, F.; Nguyen, N.; Meyring, M.; Potnick, J.R.; Santos, D.C.; Schmidt, R.; Sherer, B.; Shutes, A.; Urbahns, K.; Follis, A.V.; Wegener, A.A.; Zimmerli, S.C.; Liu-Bujalski, L. Discovery of evobrutinib: An oral, potent, and highly selective, covalent Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of immunological diseases. J. Med. Chem., 2019, 62(17), 7643-7655.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00794] [PMID: 31368705]

Montalban, X.; Wallace, D.; Genovese, M.C.; Tomic, D.; Parsons-Rich, D.; Le Bolay, C.; Kao, A.H.; Guehring, H. Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: An integrated safety analysis. J. Neurol. Neurosurg. Psychiatry, 2023, 94(1), 1-9.
[http://dx.doi.org/10.1136/jnnp-2022-328799] [PMID: 36418156]

Isenberg, D.; Furie, R.; Jones, N.S.; Guibord, P.; Galanter, J.; Lee, C.; McGregor, A.; Toth, B.; Rae, J.; Hwang, O.; Desai, R.; Lokku, A.; Ramamoorthi, N.; Hackney, J.A.; Miranda, P.; de Souza, V.A.; Jaller-Raad, J.J.; Maura Fernandes, A.; Garcia Salinas, R.; Chinn, L.W.; Townsend, M.J.; Morimoto, A.M.; Tuckwell, K. Efficacy, safety, and pharmacodynamic effects of the Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: Results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol., 2021, 73(10), 1835-1846.
[http://dx.doi.org/10.1002/art.41811] [PMID: 34042314]

Angst, D.; Gessier, F.; Janser, P.; Vulpetti, A.; Wälchli, R.; Beerli, C.; Littlewood-Evans, A.; Dawson, J.; Nuesslein-Hildesheim, B.; Wieczorek, G.; Gutmann, S.; Scheufler, C.; Hinniger, A.; Zimmerlin, A.; Funhoff, E.G.; Pulz, R.; Cenni, B. Discovery of LOU064 (Remibrutinib), a potent and highly selective covalent inhibitor of Bruton’s tyrosine kinase. J. Med. Chem., 2020, 63(10), 5102-5118.
[http://dx.doi.org/10.1021/acs.jmedchem.9b01916] [PMID: 32083858]

Kaul, M.; End, P.; Cabanski, M.; Schuhler, C.; Jakab, A.; Kistowska, M.; Kinhikar, A.; Maiolica, A.; Sinn, A.; Fuhr, R.; Cenni, B. Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clin. Transl. Sci., 2021, 14(5), 1756-1768.
[http://dx.doi.org/10.1111/cts.13005] [PMID: 33834628]

Reich, D.S.; Arnold, D.L.; Vermersch, P.; Bar-Or, A.; Fox, R.J.; Matta, A.; Turner, T.; Wallström, E.; Zhang, X.; Mareš, M.; Khabirov, F.A.; Traboulsee, A.; Grand’Maison, F.; Jacques, F.; Traboulsee, A.; Tyblova, M.; Meluzinova, E.; Ampapa, R.; Valis, M.; Hradilke, P.; Mareš, M.; Stourac, P.; Gross-Paju, K.; Laplaud, D.; Mathey, G.; Uitdehaag, B.; Evdoshenkoo, E.; Popova, E.; Zakharova, M.; Totolyan, N.; Litvinenko, I.; Khabirov, F.; Sivertseva, S.; Hancinova, V.; Kantorova, E.; Gines, M.L.M.; Montalban, X.; Maduano, S.E.; Meca-Lallana, J.; Ramió-Torrentà, L.; Nehrych, T.; Pashkovskyy, V.; Moskovko, S.; Kalbus, O.; Khavunka, M.; Pryshchepa, V.; Goloborodko, A.; Wynn, D.; Honeycutt, W.; Wray, S.; Steingo, B.; LaGanke, C.; Huang, D.; Hemphill, J.M.; Goldstick, L.; Robertson, D. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: A phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol., 2021, 20(9), 729-738.
[http://dx.doi.org/10.1016/S1474-4422(21)00237-4] [PMID: 34418400]

Dörner, T.; Furie, R. Novel paradigms in systemic lupus erythematosus. Lancet, 2019, 393(10188), 2344-2358.
[http://dx.doi.org/10.1016/S0140-6736(19)30546-X] [PMID: 31180031]

Watterson, S.H.; Liu, Q.; Beaudoin Bertrand, M.; Batt, D.G.; Li, L.; Pattoli, M.A.; Skala, S.; Cheng, L.; Obermeier, M.T.; Moore, R.; Yang, Z.; Vickery, R.; Elzinga, P.A.; Discenza, L.; D’Arienzo, C.; Gillooly, K.M.; Taylor, T.L.; Pulicicchio, C.; Zhang, Y.; Heimrich, E.; McIntyre, K.W.; Ruan, Q.; Westhouse, R.A.; Catlett, I.M.; Zheng, N.; Chaudhry, C.; Dai, J.; Galella, M.A.; Tebben, A.J.; Pokross, M.; Li, J.; Zhao, R.; Smith, D.; Rampulla, R.; Allentoff, A.; Wallace, M.A.; Mathur, A.; Salter-Cid, L.; Macor, J.E.; Carter, P.H.; Fura, A.; Burke, J.R.; Tino, J.A. Discovery of branebrutinib (BMS-986195): A strategy for identifying a highly potent and selective covalent inhibitor providing rapid in vivo inactivation of Bruton’s tyrosine kinase (BTK). J. Med. Chem., 2019, 62(7), 3228-3250.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00167] [PMID: 30893553]

Catlett, I.M.; Nowak, M.; Kundu, S.; Zheng, N.; Liu, A.; He, B.; Girgis, I.G.; Grasela, D.M. Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton’s tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants. Br. J. Clin. Pharmacol., 2020, 86(9), 1849-1859.
[http://dx.doi.org/10.1111/bcp.14290] [PMID: 32198939]

Haselmayer, P.; Camps, M.; Liu-Bujalski, L.; Nguyen, N.; Morandi, F.; Head, J.; O’Mahony, A.; Zimmerli, S.C.; Bruns, L.; Bender, A.T.; Schroeder, P.; Grenningloh, R. Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models. J. Immunol., 2019, 202(10), 2888-2906.
[http://dx.doi.org/10.4049/jimmunol.1800583] [PMID: 30988116]

Ran, F.; Liu, Y.; Wang, C.; Xu, Z.; Zhang, Y.; Liu, Y.; Zhao, G.; Ling, Y. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. Eur. J. Med. Chem., 2022, 229, 114009.
[http://dx.doi.org/10.1016/j.ejmech.2021.114009] [PMID: 34839996]

Wen, T.; Wang, J.; Shi, Y.; Qian, H.; Liu, P. Inhibitors targeting Bruton’s tyrosine kinase in cancers: Drug development advances. Leukemia, 2021, 35(2), 312-332.
[http://dx.doi.org/10.1038/s41375-020-01072-6] [PMID: 33122850]

Adasme, M.F.; Parisi, D.; Van Belle, K.; Salentin, S.; Haupt, V.J.; Jennings, G.S.; Heinrich, J.C.; Herman, J.; Sprangers, B.; Louat, T.; Moreau, Y.; Schroeder, M. Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor. PLoS One, 2020, 15(5), e0233089.
[http://dx.doi.org/10.1371/journal.pone.0233089] [PMID: 32459810]

Shen, P.; Wang, Y.; Jia, X.; Xu, P.; Qin, L.; Feng, X.; Li, Z.; Qiu, Z. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases. Eur. J. Med. Chem., 2022, 239, 114551.
[http://dx.doi.org/10.1016/j.ejmech.2022.114551] [PMID: 35749986]

Rotondo, J.C.; Bononi, I.; Puozzo, A.; Govoni, M.; Foschi, V.; Lanza, G.; Gafà, R.; Gaboriaud, P.; Touzé, F.A.; Selvatici, R.; Martini, F.; Tognon, M. Merkel cell carcinomas arising in autoimmune disease affected patients treated with biologic drugs, Including anti-TNF. Clin. Cancer Res., 2017, 23(14), 3929-3934.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-2899] [PMID: 28174236]